BCRX vs. SO

Last updated Jul 11, 2026

BCRX (BioCryst Pharmaceuticals, Inc.) and SO (The Southern Company) are both stocks. BCRX operates in Biotechnology (Healthcare), while SO operates in Utilities - Regulated Electric (Utilities). Over the past 10 years, BCRX returned 13.03%/yr vs 10.67%/yr for SO. At a 0.05 correlation, their price movements are largely independent.

Performance

BCRX vs. SO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in BioCryst Pharmaceuticals, Inc. (BCRX) and The Southern Company (SO). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, BCRX achieves a 33.97% return, which is significantly higher than SO's 12.27% return. Over the past 10 years, BCRX has outperformed SO with an annualized return of 13.03%, while SO has yielded a comparatively lower 10.67% annualized return.

BCRX

• 1D: -2.52%
• 1M: 20.11%
• 6M: 41.22%
• YTD: 33.97%
• 1Y: 19.29%
• 3Y*: 13.27%
• 5Y*: -8.57%
• 10Y*: 13.03%

SO

• 1D: 0.46%
• 1M: 2.04%
• 6M: 12.52%
• YTD: 12.27%
• 1Y: 7.37%
• 3Y*: 14.81%
• 5Y*: 13.52%
• 10Y*: 10.67%

*Multi-year figures are annualized to reflect compound growth (CAGR)

BCRX vs. SO - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
BCRX BioCryst Pharmaceuticals, Inc.	33.97%	3.72%	25.54%	-47.82%	-17.11%	85.91%	115.94%	-57.25%	64.36%	-22.43%
SO The Southern Company	12.27%	9.47%	21.72%	2.21%	8.24%	16.34%	0.63%	51.65%	-3.75%	2.42%

Correlation

The correlation between BCRX and SO is 0.04, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.04
Correlation (3Y) Calculated over the trailing 3-year period	0.05
Correlation (5Y) Calculated over the trailing 5-year period	0.06
Correlation (10Y) Calculated over the trailing 10-year period	0.03
Correlation (All Time) Calculated using the full available price history since Mar 4, 1994	0.05

Fundamentals

Market Cap BCRX : $2.19B SO : $107.78B
EPS BCRX : -$2.02 SO : $3.91
PS Ratio BCRX : 2.68 SO : 3.54
Total Revenue (TTM) BCRX : $885.72M SO : $30.17B
Gross Profit (TTM) BCRX : $167.34M SO : $13.01B
EBITDA (TTM) BCRX : -$374.88M SO : $14.44B

Return for Risk

BCRX vs. SO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BCRX

BCRX Risk / Return Rank: 58
BCRX Sharpe Ratio Rank: 59
BCRX Sortino Ratio Rank: 58
BCRX Omega Ratio Rank: 54
BCRX Calmar Ratio Rank: 59
BCRX Martin Ratio Rank: 58

SO

SO Risk / Return Rank: 55
SO Sharpe Ratio Rank: 59
SO Sortino Ratio Rank: 51
SO Omega Ratio Rank: 50
SO Calmar Ratio Rank: 56
SO Martin Ratio Rank: 57

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BCRX vs. SO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for BioCryst Pharmaceuticals, Inc. (BCRX) and The Southern Company (SO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	BCRX	SO	Difference
Sharpe ratio: Return per unit of total volatility	0.38	0.40	-0.02
Sortino ratio: Return per unit of downside risk	0.97	0.70	+0.27
Omega ratio: Gain probability vs. loss probability	1.11	1.08	+0.03
Calmar ratio: Return relative to maximum drawdown	0.58	0.45	+0.14
Martin ratio: Return relative to average drawdown	1.20	1.04	+0.16

BCRX vs. SO - Sharpe Ratio Comparison

The current BCRX Sharpe Ratio is 0.38, which is comparable to the SO Sharpe Ratio of 0.40. The chart below compares the historical Sharpe Ratios of BCRX and SO, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

BCRX vs. SO - Drawdown Comparison

The maximum BCRX drawdown since its inception was -97.74%, which is greater than SO's maximum drawdown of -38.43%. Use the drawdown chart below to compare losses from any high point for BCRX and SO.

Drawdown Indicators

	BCRX	SO	Difference
Max Drawdown Largest peak-to-trough decline	-97.74%	-38.43%	-59.31%
Max Drawdown (1Y) Largest decline over 1 year	-30.36%	-14.99%	-15.37%
Max Drawdown (3Y) Largest decline over 3 years	-47.85%	-14.99%	-32.86%
Max Drawdown (5Y) Largest decline over 5 years	-79.10%	-23.28%	-55.82%
Max Drawdown (10Y) Largest decline over 10 years	-83.69%	-38.43%	-45.26%
Current Drawdown Current decline from peak	-68.46%	-2.42%	-66.04%
Average Drawdown Average peak-to-trough decline	-69.64%	-6.86%	-62.78%
Ulcer Index Depth and duration of drawdowns from previous peaks	14.73%	6.43%	+8.30%

Volatility

BCRX vs. SO - Volatility Comparison

BioCryst Pharmaceuticals, Inc. (BCRX) has a higher volatility of 15.21% compared to The Southern Company (SO) at 5.70%. This indicates that BCRX's price experiences larger fluctuations and is considered to be riskier than SO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	BCRX	SO	Difference
Volatility (1M) Calculated over the trailing 1-month period	15.21%	5.70%	+9.51%
Volatility (6M) Calculated over the trailing 6-month period	36.41%	13.52%	+22.89%
Volatility (1Y) Calculated over the trailing 1-year period	46.57%	16.74%	+29.83%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	62.20%	18.69%	+43.51%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	72.65%	21.99%	+50.66%

Dividends

BCRX vs. SO - Dividend Comparison

BCRX has not paid dividends to shareholders, while SO's dividend yield for the trailing twelve months is around 3.87%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
BCRX BioCryst Pharmaceuticals, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SO The Southern Company	3.87%	3.37%	3.47%	3.96%	3.78%	3.82%	4.13%	3.86%	5.42%	4.78%	4.52%	4.60%

Financials

Frequently Asked Questions

Can I hold both BCRX and SO in my portfolio?

BCRX and SO have a correlation of 0.04, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, BCRX or SO?

BCRX has higher volatility (15.21%) compared to SO (5.70%). In terms of maximum drawdown, BCRX dropped -97.74% vs SO's -38.43%.

Which has better risk-adjusted returns?

SO currently has the higher Sharpe Ratio (0.40 vs 0.38), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.